Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings.
Gray
Andy
A
Abdool Karim
Salim S
SS
Gengiah
Tanuja N
TN
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000904:Antibiotics, Antitubercular / Q000009:adverse effects; D003906:Developing Countries; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D012293:Rifampin / Q000009:adverse effects; D019438:Ritonavir / Q000009:adverse effects*; D019258:Saquinavir / Q000009:adverse effects*; D014376:Tuberculosis / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D017320:HIV Protease Inhibitors; D019258:Saquinavir; D019438:Ritonavir; D012293:Rifampin